Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 2/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9477965 | 0.79 | CES1 (0.42) | CES2CES1TSHRTDP1 | |
| SCHEMBL4655343 | 0.77 | TSHR (0.33) | TSHRTDP1 | |
| SCHEMBL4655167 | 0.77 | — | — | |
| SCHEMBL1986410 | 0.75 | — | — | |
| SCHEMBL83007 | 0.73 | — | — | |
| SCHEMBL11845950 | 0.72 | — | — | |
| SCHEMBL9494181 | 0.70 | HDAC3 (0.33) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL13317699 | 0.70 | HDAC3 (0.33) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL1275421 | 0.70 | CA1 (0.37) | — | |
| SCHEMBL3280806 | 0.70 | CES1 (0.41) | HDAC3HDAC1HDAC2HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2718016-B1 | NEW COMPLEXES OF RUTHENIUM, METHOD FOR THEIR PREPARATION, AND THEIR APPLICATION IN OLEFIN METATHESIS REACTIONS | UMICORE AG & CO KG (DE) | 2019-08-14 | — | — | EP | disclosed |
| US-9802927-B2 | Oxadiazine compounds and methods of use thereof | DENALI THERAPEUTICS, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-9771378-B2 | Fused morpholinopyrimidines and methods of use thereof | DENALI THERAPEUTICS, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-20170066753-A1 | OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF | DENALI THERAPEUTICS, INC. | 2017-03-09 | — | — | US | disclosed |
| US-20170044182-A1 | FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF | FORUM PHARMACEUTICALS INC. | 2017-02-16 | — | — | US | disclosed |
| WO-2016201168-A1 | OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF | FORUM PHARMCEUTICALS INC. (US) | 2016-12-15 | — | — | WO | disclosed |
| WO-2015109109-A1 | FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF | FORUM PHARMACEUTICALS INC. (US) | 2015-07-23 | — | — | WO | disclosed |
| WO-2015066697-A1 | FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF | FORUM PHARMACEUTICALS INC. (US) | 2015-05-07 | — | — | WO | disclosed |
| WO-2015066696-A1 | FUSED MORPHLINOPYRIMIDINES AND METHODS OF USE THEREOF | FORUM PHARMACEUTICALS INC. (US) | 2015-05-07 | — | — | WO | disclosed |
| EP-2718016-A1 | NEW COMPLEXES OF RUTHENIUM, METHOD FOR THEIR PREPARATION, AND THEIR APPLICATION IN OLEFIN METATHESIS REACTIONS | Umicore AG & Co. KG (DE) | 2014-04-16 | — | — | EP | disclosed |
| WO-2007109633-A2 | ORGANOTELLURIUM AND SELENIUM-BASED ANTIMICROBIAL ANTIMICROBIAL FORMULATIONS AND ARTICLES | ANDOVER HEALTHCARE, INC. (US) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007025009-A2 | INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2007-03-01 | — | — | WO | disclosed |
| US-20070049555-A1 | Indenoisoquinolinone analogs and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2007-03-01 | — | — | US | disclosed |
| US-20060287313-A1 | Isoquinoline compounds and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2006-12-21 | — | — | US | disclosed |
| US-20060287312-A1 | Tetracyclic amino and carboxamido compounds and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2006-12-21 | — | — | US | disclosed |
| US-20060287311-A1 | Tetracyclic Sulfonamide Compounds and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2006-12-21 | — | — | US | disclosed |
| WO-2006093667-A1 | TETRACYCLIC AMINO AND CARBOXAMIDO COMPOUNDS AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2006-09-08 | — | — | WO | disclosed |
| WO-2006094012-A2 | PENTACYCLIC ALKALOID COMPOUNDS AND METHODS OF USE THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2006-09-08 | — | — | WO | disclosed |
| WO-2006093666-A2 | ISOQUNOLINE COMPOUNDS AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2006-09-08 | — | — | WO | disclosed |
| WO-2006093677-A1 | TETRACYCLIC SULFONAMIDE COMPOUNDS AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2006-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170066753-A1 | OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF | PSEN2, SMN1; SMN2, OTC | HDAC3 902/4885HDAC1 623/4885HDAC2 574/4885 |
| US-20170044182-A1 | FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF | SMN1; SMN2, FUS, SYNCRIP | HDAC3 2992/4885HDAC1 2428/4885HDAC2 3367/4885 |
| US-20070049555-A1 | Indenoisoquinolinone analogs and methods of use thereof | TNNI3, IDH2, GLS | HDAC3 1841/4885HDAC1 1223/4885HDAC2 1522/4885 |
| US-20060287313-A1 | Isoquinoline compounds and methods of use thereof | GLS, PINK1, PARK7 | HDAC3 1769/4885HDAC1 2006/4885HDAC2 1186/4885 |
| US-20060287311-A1 | Tetracyclic Sulfonamide Compounds and methods of use thereof | TST, SNCA, TXNRD2 | HDAC3 1707/4885HDAC1 1019/4885HDAC2 666/4885 |
| US-20060287312-A1 | Tetracyclic amino and carboxamido compounds and methods of use thereof | GLS, AADAT, IAPP | HDAC3 2162/4885HDAC1 1486/4885HDAC2 1470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.